WHO Adapts Ebola Vaccination Strategy in the DRC to Account for Insecurity and Community Feedback 08/05/2019 Editorial team [WHO News Release] WHO’s Strategic Advisory Group of Experts (SAGE) today issued new recommendations to address vaccination challenges in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC). Image Credits: WHO/J. D. Kannah. Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> Surge In Demand Spurs Market-Opening Initiatives In China’s Healthcare Market 20/11/2018 John Zarocostas SHANGHAI, China - A surge in demand for better healthcare coverage and outcomes and widespread calls for a reduction in high medical treatment costs are driving structural reforms and market-opening initiatives in China's rapidly expanding healthcare market, industry executives, officials and experts have said. The market is forecast to increase from $761 billion in 2017 to nearly $2.4 trillion by 2030. Continue reading -> Index Finds Five Companies Develop Majority Of Medicines For Poor 20/11/2018 David Branigan A global index on access to medicine has found that the majority of the medicines needed by the world’s poor are developed by only five companies, and that these medicines are focused primarily on just five diseases. The group behind the index calls on more pharmaceutical companies to join efforts for increased access and to expand the list of medicines, in order to build resilience in treating diseases that affect the poor. Continue reading -> WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> Surge In Demand Spurs Market-Opening Initiatives In China’s Healthcare Market 20/11/2018 John Zarocostas SHANGHAI, China - A surge in demand for better healthcare coverage and outcomes and widespread calls for a reduction in high medical treatment costs are driving structural reforms and market-opening initiatives in China's rapidly expanding healthcare market, industry executives, officials and experts have said. The market is forecast to increase from $761 billion in 2017 to nearly $2.4 trillion by 2030. Continue reading -> Index Finds Five Companies Develop Majority Of Medicines For Poor 20/11/2018 David Branigan A global index on access to medicine has found that the majority of the medicines needed by the world’s poor are developed by only five companies, and that these medicines are focused primarily on just five diseases. The group behind the index calls on more pharmaceutical companies to join efforts for increased access and to expand the list of medicines, in order to build resilience in treating diseases that affect the poor. Continue reading -> WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> Surge In Demand Spurs Market-Opening Initiatives In China’s Healthcare Market 20/11/2018 John Zarocostas SHANGHAI, China - A surge in demand for better healthcare coverage and outcomes and widespread calls for a reduction in high medical treatment costs are driving structural reforms and market-opening initiatives in China's rapidly expanding healthcare market, industry executives, officials and experts have said. The market is forecast to increase from $761 billion in 2017 to nearly $2.4 trillion by 2030. Continue reading -> Index Finds Five Companies Develop Majority Of Medicines For Poor 20/11/2018 David Branigan A global index on access to medicine has found that the majority of the medicines needed by the world’s poor are developed by only five companies, and that these medicines are focused primarily on just five diseases. The group behind the index calls on more pharmaceutical companies to join efforts for increased access and to expand the list of medicines, in order to build resilience in treating diseases that affect the poor. Continue reading -> WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Surge In Demand Spurs Market-Opening Initiatives In China’s Healthcare Market 20/11/2018 John Zarocostas SHANGHAI, China - A surge in demand for better healthcare coverage and outcomes and widespread calls for a reduction in high medical treatment costs are driving structural reforms and market-opening initiatives in China's rapidly expanding healthcare market, industry executives, officials and experts have said. The market is forecast to increase from $761 billion in 2017 to nearly $2.4 trillion by 2030. Continue reading -> Index Finds Five Companies Develop Majority Of Medicines For Poor 20/11/2018 David Branigan A global index on access to medicine has found that the majority of the medicines needed by the world’s poor are developed by only five companies, and that these medicines are focused primarily on just five diseases. The group behind the index calls on more pharmaceutical companies to join efforts for increased access and to expand the list of medicines, in order to build resilience in treating diseases that affect the poor. Continue reading -> WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Index Finds Five Companies Develop Majority Of Medicines For Poor 20/11/2018 David Branigan A global index on access to medicine has found that the majority of the medicines needed by the world’s poor are developed by only five companies, and that these medicines are focused primarily on just five diseases. The group behind the index calls on more pharmaceutical companies to join efforts for increased access and to expand the list of medicines, in order to build resilience in treating diseases that affect the poor. Continue reading -> WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Expert Group On Immunization Highlights Global Vaccination Progress, Challenges 30/10/2018 David Branigan The World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization met from 23-25 October to review progress and recommendations for the Global Vaccine Action Plan, including the need for guidance on the use of Ebola vaccines in emergencies, the contribution of human papillomavirus (HPV) vaccination toward eliminating cervical cancer, and the current status of polio and measles eradication, according to a press briefing. Continue reading -> WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO, UNICEF, Pharma Meet On Supply Chains And Medicines Access 20/08/2018 William New The World Health Organization, UNICEF, and member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) will meet this week at WHO in Geneva to discuss global and regional supply chain strategies and initiatives related to global health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy